FBS origin is one of the most important selection criteria for regulated applications. The collection country determines BSE/TSE risk classification, available regulatory documentation, acceptance by EU and US regulatory agencies, and often price. For research applications, origin is less critical — but for GMP manufacturing, ATMP production, and diagnostic kit development, origin documentation is part of the regulatory submission.
| Origin | BSE/TSE Risk (OIE) | CEP Available | FDA 9CFR Compliance | EMA Acceptance | Typical Use |
|---|
| EU (Germany, France, Ireland…) | Controlled — monitored, low risk. EU surveillance programme. | ✅ Yes — EDQM CEP for most lots | ⚠️ US import restrictions apply for some EU countries | ✅ Fully accepted — preferred for EU submissions | EU regulatory submissions, EMA-aligned ATMP documentation, diagnostic kit IVDR compliance |
| USA | Controlled — USDA monitoring. BSE negligible risk since 2013. | ⚠️ Not standard — Ph. Eur. CEP rarely issued for US origin | ✅ 9CFR compliant — FDA registered facilities | ✅ Accepted — with 9CFR CoA | US regulatory submissions (IND/BLA), FDA-aligned DMPK studies, cost-sensitive research |
| South America (Uruguay, Brazil, Argentina) | Controlled — OIE negligible risk category for Uruguay/Argentina. Brazil: controlled. | ✅ Available for some lots (EDQM CEP) | ⚠️ USDA import restrictions — not permitted for certain US applications | ✅ Accepted with CEP documentation | High-volume research and manufacturing where cost is primary driver. CEP provides EU regulatory path. |
| Australia / New Zealand | ✅ Negligible — highest biosafety profile. No indigenous BSE. | ✅ Yes — EDQM CEP available | ✅ USDA import allowed — approved origin | ✅ Fully accepted | Applications requiring maximum BSE documentation, clean regulatory submissions, safety-critical manufacturing |
| Application | Recommended Origin | Reason |
|---|
| EU regulatory submission (EMA, national CA) | EU or South American with CEP | EMA prefers EU origin or CEP-documented lots for ancillary materials |
| US regulatory submission (FDA IND/BLA) | US origin (9CFR) or Australian | USDA restrictions on some South American lots; US and Australian origin straightforward for FDA |
| ATMP manufacturing (Phase I/II) | EU or Australian | Maximum TSE/BSE documentation, CEP available, lowest risk profile |
| IVD kit development (IVDR) | EU or South American with CEP | IVDR 2017/746 requires traceability — CEP simplifies documentation |
| General research (no regulatory filing) | South American or US | Best value — regulatory documentation not required |
| Maximum biosafety / prion risk minimisation | Australia / New Zealand | No indigenous BSE — highest achievable TSE/BSE safety profile |
